CorVita provides a universal AED adapter that bridges the connector gap between different AED brands and their pads. Its multi‑port, plug‑and‑play design with built‑in electronic signal conversion lets any compatible pad be used on any AED, reducing delays during cardiac arrest emergencies for first responders, healthcare facilities, schools, and public venues.
Funding
$131.3K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Automated External Defibrillators (AEDs) use proprietary pad connectors, so responders must match the correct pad to each device. This incompatibility forces extra steps during a sudden cardiac arrest, causing critical delays in delivering life‑saving shocks.
Solution
CorVita offers a universal AED adapter that bridges the connector gap between different AED brands and their pads. The adapter incorporates a multi‑port interface and built‑in electronic signal conversion to translate pad signals so any compatible pad can be used with any AED. By eliminating the need to locate brand‑specific pads, the device streamlines the rescue workflow and reduces the time to first shock. The solution is being developed for FDA clearance and is protected by pending design and utility patents, ensuring regulatory compliance and intellectual‑property protection.
Target Audience
Primary customers include first‑responder agencies (fire, EMS, law enforcement), hospitals and healthcare facilities, educational campuses, and public venues such as airports, hotels, and corporate safety programs that maintain multiple AED brands.
Features
- Multi‑port interface supporting the major AED pad connector standards
- Integrated electronic signal conversion for reliable pad‑to‑AED communication
- Plug‑and‑play design requiring no additional configuration or software
- Compact, rugged housing suitable for emergency response kits and public installations
- Patent‑pending design that safeguards the technology while pursuing FDA clearance